What is he best known for?
The fields of study he is best known for:
His scientific interests lie mostly in Immunology, Antibody, Lymphoma, Follicular lymphoma and Immune system.
His biological study spans a wide range of topics, including Molecular biology, B-cell lymphoma, Toxicity and Virology.
Many of his studies involve connections with topics such as Monoclonal and Lymphoma.
His Follicular lymphoma study combines topics in areas such as Mutation, Tumor progression, Cancer research and Immunoglobulin G.
His Immune system research is multidisciplinary, relying on both Cancer and Ex vivo.
Ronald Levy focuses mostly in the field of Diffuse large B-cell lymphoma, narrowing it down to topics relating to BCL6 and, in certain cases, Gene expression profiling.
His most cited work include:
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (8095 citations)
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (2532 citations)
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells (1729 citations)
What are the main themes of his work throughout his whole career to date?
Ronald Levy mainly focuses on Immunology, Antibody, Lymphoma, Cancer research and Antigen.
His research on Immunology frequently links to adjacent areas such as Cytotoxic T cell.
The concepts of his Antibody study are interwoven with issues in Molecular biology and B-cell lymphoma.
Follicular lymphoma, Diffuse large B-cell lymphoma and Rituximab are the subjects of his Lymphoma studies.
His studies deal with areas such as BCL6 and Oncology as well as Diffuse large B-cell lymphoma.
His research in Cancer research intersects with topics in Cancer, Mantle cell lymphoma, Germinal center and Ibrutinib.
He most often published in these fields:
- Immunology (42.86%)
- Antibody (32.99%)
- Lymphoma (31.80%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (24.83%)
- Lymphoma (31.80%)
- Immune system (19.90%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Cancer research, Lymphoma, Immune system, Immunotherapy and Antibody.
Ronald Levy has researched Cancer research in several fields, including Cancer, CD8 and T cell.
His Lymphoma study combines topics from a wide range of disciplines, such as Ibrutinib and Oncology.
The study incorporates disciplines such as Peripheral blood mononuclear cell and Vaccination in addition to Immune system.
Immunology covers Ronald Levy research in Antibody.
His work on Acquired immune system as part of general Immunology study is frequently linked to Extramural, bridging the gap between disciplines.
Between 2016 and 2021, his most popular works were:
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma (1549 citations)
- Eradication of spontaneous malignancy by local immunotherapy (183 citations)
- Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody (140 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Immune system
His primary areas of study are Cancer research, Immune system, Lymphoma, Cancer and Antibody.
His Cancer research study incorporates themes from Cytotoxic T cell, CD8 and Immunotherapy.
Ronald Levy combines subjects such as Progression-free survival and Oncology with his study of Lymphoma.
In the field of Cancer, his study on Cancer immunotherapy overlaps with subjects such as TLR9.
His Antibody study is concerned with Immunology in general.
The Immunoglobulin Idiotypes, Immunoglobulin genes, Somatic hypermutation and HLA-D Antigens research Ronald Levy does as part of his general Immunology study is frequently linked to other disciplines of science, such as Extramural, therefore creating a link between diverse domains of science.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
